Xyotax is a form of the anticancer drug paclitaxel combined with a protein called poliglumex that may have fewer side effects and work better than paclitaxel. It is being studied in the treatment of breast cancer, ovarian cancer, lung cancer, and other types of cancer. It belongs to the family of drugs called mitotic inhibitors. Also called CT-2103, paclitaxel poliglumex, and paclitaxel polyglutamate.
Cell Therapeutics, Inc. announced encouraging interim results of a phase II clinical study of OPAXIO combined with temozolomide and radiotherapy in patients with newly diagnosed high-grade malignant brain tumors.
Cell Therapeutics, Inc. announced that data from a study with OPAXIO, in patients with newly diagnosed high-grade gliomas, and interim results from a study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia, will be presented at the 2011 American Society of Clinical Oncology Annual Meeting, which will be held June 3-7, 2011, in Chicago, Illinois. Both studies were selected for oral poster discussion sessions.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
Cell Therapeutics, Inc. announced the preliminary results of a phase II study of paclitaxel poliglumex (OPAXIO) combined with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed high-grade gliomas.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO (paclitaxel poliglumex) in patients with advanced esophageal cancer demonstrated that 38% (15/40) patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
Cell Therapeutics, Inc. announced today that, in a study from Brown University to be presented by Howard Safran, M.D., head of the Brown University Oncology Group, in the proffered oral session at the Annual Meeting of the International Society of Gastrointestinal Oncology (ISGIO) in Philadelphia, Pennsylvania patients with cancer of the lower esophagus demonstrated a high rate of complete remission (CR) when given OPAXIO(TM) (paclitaxel poliglumex), a biologically enhanced paclitaxel, when administered in combination with standard cisplatin and concurrent radiation.
At the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), data were presented from a phase II investigator-sponsored trial paclitaxel poliglumex (Opaxio, CT-2103) in combination with capecitabine in first-line treatment of patients with metastatic breast cancer (MBC).
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.